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radiotherapy was US $412.14 (SD: US $46.52). The mean cost per patient in each 
clinical stage to chemotherapy was I: US $3166.99 (SD: US $2258.67), II: US 
$3843.45 (SD: US $1381.09), III: US $5254.36 (SD: US $922.43), IV: US $2500.40 
(SD: US $1323.60) and the non classiﬁed: US $2565.25 (SD: US $1356.95) p 0.551. 
CONCLUSIONS: The results show that in México, in more expensive the treatment 
to patients with non-hodgkin lymphoma in clinical stage III.
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OBJECTIVES: To describe costs associated to the treatment of different stages of 
breast cancer patients at the Social Security Mexican Institute (IMSS) from the health 
care payer’s perspective. METHODS: A cost study was elaborated. Resource use and 
cost data were obtained from hospital (second and tertiary levels) records of 313 of 
treated patients during July 2008 to February 2009 using the following inclusion 
criteria: women older than 16 years with breast cancer histological diagnosis who 
accepted to be included in the protocol through informed consent. Although, patients 
excluded were those who showed a second malignant neoplasm or incomplete infor-
mation. We calculate mean, median, 95% conﬁdence interval (95% CI) for each clini-
cal stage and statistical differences were estimated through ANOVA tests, p value 
<0.05 was considered signiﬁcant to show differences. RESULTS: The median total 
cost per patient was found in US $6135.38 (95% CI, US $4216.19–US $9737.19); 
the median cost per chemotherapy cycle was US $615.48 (95% CI, US $425.98–US 
$1456.63); all chemotherapy treatment resulted in US $2702.03, (95% CI, US 
$1456.36–US $5503.49) and median costs per patient with radiotherapy resulted in 
US $1260.78 (95% CI, US $421.34–US $1260.78). The mean cost per patient in each 
clinical stage with chemotherapy was: I: US $1830.80 (95% CI, US $686.21–
$2975.39); II: US $5143.41 (95% CI, US $3570.19–$6716.62); III: US $4079.77 
(95% CI, US $2739.86–$5419.68); IV: US $4907.21 (95% CI, US $672.11–$9142.31) 
and the non classiﬁed patients: US $5250.66 (95% CI, US $3360.94–$7140.40); p = 
0.401. CONCLUSIONS: The results showed that at the IMSS, it is more expensive 
the treatment of breast cancer patients in clinical stage II; however, the less expensive 
treatments resulted for patients in clinical stage I. In addition, the treatment of non 
classiﬁed patients were the second most expensive according to our results.
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OBJECTIVES: To describe cost associated to the treatment of different stages of 
colorectal cancer at the Social Security Mexican Institute (IMSS) from the health care 
payer’s perspective. METHODS: A cost study was made. Resource use and cost data 
were obtained from hospital (second and tertiary levels) records of 115 treated patients 
from July 2008 to February 2009 using the following inclusion criteria: patients older 
than 16 years with colorectal cancer histological diagnosis who accepted to be 
included in the protocol through informed consent. Although, patients excluded were 
those who showed a second malignant neoplasm or incomplete information. We 
calculate mean,standard deviation (SD), median, 25 percentil and 75 percentil for each 
clinical stage and statistical differences were estimated through ANOVA tests, p value 
<0.05 was considered signiﬁcant to show differences. RESULTS: The median total 
cost per patient was US $3,263.52 (US $2,111.29 to US $4,881.14), the mean cost 
per chemotherapy was US $484.16 (SD: US $113.95), mean cost to radiotherapy was 
US $402.40 (SD: US $57.20). The mean cost per patient in each clinical stage to 
chemotherapy was I: US $247.21 (SD: US $247.21), II: US $482.48 (SD: US $208.96), 
III: US $393.75 (SD: US $192.35), IV: US $986.17 (SD: US $631.59) and the non 
classiﬁed: US $386.88 (SD: US $105.18) p 0.521. CONCLUSIONS: The results show 
that in México, in more expensive the treatment to patients with colorectal cancer in 
clinical stage IV, the cheapest treatment was to patients in clinical stage I, the treatment 
to clinical stage II patients are the second most expensive according our results, prob-
ably associated to longer hospital stay.
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OBJECTIVES: Novel chemotherapies for metastatic breast cancer (MBC), such as 
bevacizumab, have the potential to extend progression-free survival but with a ﬁnan-
cial burden to health systems. We estimate the cost-effectiveness of bevacizumab in 
combination with paclitaxel as compared to paclitaxel alone from the perspective of 
the United States Medicare system. METHODS: We constructed a hybrid decision 
tree-Markov model to follow a cohort for ten years composed of 10,000 women ages 
65 and older with a diagnosis of MBC and no prior chemotherapy in the metastatic 
setting. Individuals in the model transitioned between three distinct states: stable 
disease, progressive disease, and death. Transition probabilities, cost and outcome 
data were obtained from clinical trials, published Medicare reimbursement rates, and 
the peer-reviewed literature. Incremental costs per quality-adjusted life year (QALY) 
were valued in 2009 US dollars. We discounted costs and survival at 3% per year. 
Deterministic and probabilistic sensitivity analyses tested the robustness of the model 
to variation in key parameters. RESULTS: In the base-case scenario, the bevacizumab 
plus paclitaxel arm had 22 additional days in quality-adjusted survival at an additional 
cost of $104,102 per patient, resulting in an incremental cost-effectiveness ratio 
(ICER) of $1.7 million/QALY. In the probabilistic sensitivity analysis, the ICER plane 
of 1,000 Monte Carlo simulation trials resulted in bevacizumab being more costly and 
more effective in 66.8% of samples and the dominated strategy in 34.1% of samples. 
In the deterministic sensitivity analysis, results were robust to changes in cost and 
utility parameters. Variation in time in progressive state and overall survival resulted 
in higher costs and slightly better outcomes; however, none of the sensitivity tests had 
positive ICERs below $50,000/QALY. CONCLUSIONS: Given the high cost in rela-
tion to its survival beneﬁts, it is unlikely that adding bevacizumab for MBC would be 
a cost-effective allocation of Medicare resources.
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OBJECTIVES: Cisplatin is a chemotherapeutic agent which is widely used and studied 
for multiple cancer types; however certain types of toxicity (ototoxicity, nephrotoxic-
ity and neurotoxicity) are associated with Cisplatin. Preclinical studies, performed on 
human testicular cancer cell lines, have indicated that combining Cisplatin with a Src 
Inhibitor (KX1–004) may signiﬁcantly mitigate toxicity related damage. To utilize the 
results from preclinical studies examining the beneﬁt of combining Cisplatin with 
KX1–004 in conjunction with cost of illness estimates from the literature to estimate 
the potential economic beneﬁts which could result from KX1–004 utilization. 
METHODS: Data from preclinical studies examining the toxicity limiting efﬁcacy of 
KX1–004 was combined with clinical and economic data from the literature with 
respect to the estimated cost of health care resources related to the speciﬁed toxic 
effects. This efﬁcacy and costing information was combined within a decision tree 
model to estimate the potential cost savings. RESULTS: The preclinical data indicates 
that KX1–004 may have a protective effect with respect to the neurotoxic, nephrotoxic 
(22% less damage) and ototoxic (82% less damage) effects. The Src inhibitor, when 
used alone and in conjunction with Cisplatin, exhibited the potential to slow tumor 
growth and maintain overall body mass. The economic modeling resulted in a poten-
tial per patient cost savings of $1633 resulting from mitigation of the ototoxic and 
nephrotoxic effects. CONCLUSIONS: Recent research has indicated that Cisplatin 
should be considered as a component of the standard therapy regimen for certain 
cancer types; however toxicity remains a signiﬁcant concern. When Cisplatin is used 
within a regimen which includes KX1–004, the beneﬁts may include decreased damage 
due to toxicity and an improvement in quality of life. The Src inhibitor may also 
provide a survival beneﬁt by enabling patients to remain on a regimen which includes 
Cisplatin.
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OBJECTIVES: Clinical trials have shown a statistically signiﬁcant disease-free survival 
beneﬁt of oxaliplatin or irinotecan based combination therapy for stage IV colon 
cancer. However, less is known regarding the comparative effectiveness and cost-
effectiveness of these agents among elderly patients. Whether the additional beneﬁt of 
these two agents is worth the additional cost for elderly Medicare recipients is particu-
larly policy relevant. METHODS: A cost-effectiveness analysis of oxaliplatin or iri-
notecan based combination therapy versus 5-ﬂuorouracil/leucovorin (5FU/LV) in 
patients aged 66 or older with stage IV colon cancer was performed from a US Medi-
care health care payer perspective. Survival and direct medical costs were estimated 
using patient-level data from the 1997–2007 surveillance, epidemiology, and 
end results (SEER)-Medicare datasets for patients diagnosed through 2005. Incremen-
tal cost-effectiveness ratio (ICER) was calculated and expressed as cost per life-year 
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gained. RESULTS: Patients were categorized into 5FU/LV (n = 2,834), oxaliplatin 
based (n = 621), and irinotecan based (n = 945) subgroups, based on the regimen they 
received. The median improvement in overall survival with 5FU/LV, irinotecan or 
oxaliplatin based combination therapy was 1.25, 1.34, and 1.72 life-years, respec-
tively. The incremental cost with irinotecan or oxaliplatin based combination therapy 
compared with 5FU/LV was $205,837 and $93,651, respectively. When comparing 
to irinotecan based combination therapy, the incremental cost-effectiveness ratio 
of oxaliplatin based combination therapy was $67,637 per life-year gained. 
CONCLUSIONS: This analysis suggests that oxaliplatin or irinotecan based combina-
tion therapy improves overall survival but also substantially increases direct medical 
costs compared with 5FU/LV when used in elderly US patients with stage IV colon 
cancer. Oxaliplatin-based regimens are more cost-effective than irinotecan based 
regimens.
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OBJECTIVES: The cost-effectiveness of cetuximab has been controversial mainly 
because of its marginal clinical beneﬁts at very high medication cost. This study 
examines the cost-effectiveness of cetuximab versus best supportive care in the patients 
with metastatic colorectal cancer in US from the perspective of Medicare. METHODS: 
As modeled in a decision tree, three treatment options (cetuximab, cetuximab plus 
irinotecan, and best supportive care) are evaluated clinically and economically. Costs 
of cetuximab treatment options are largely determined by the treatment responses: 
complete or partial responsive, stable disease, or progressive, and whether or not the 
patient experienced severe infusion reaction and/or severe adverse events. The primary 
outcome is quality-adjusted life expectancy. The treatment response rates and quality 
of life measurements are based on the results from clinical trials. Incremental cost-
effectiveness ratios (ICER) between cetuximab treatments and best supportive care are 
presented to demonstrate the value of cetuximab treatments. Finally, sensitivity analy-
ses are conduct to test the robustness of the results. RESULTS: In the patients with 
metastatic colorectal caner, the incremental cost per quality-adjusted life year (QALY) 
was $336,218 for cetuximab, and $318,609 for cetuximab plus irinotecan, in com-
parison with best supportive care. One-way sensitivity analyses showed that the cost 
of cetuximab had the highest impact on ICERs, compared to other costs and quality 
of life parameters. Probabilistic sensitivity analyses by Monte Carlo simulation dem-
onstrated that best supportive care is more cost-effective than cetuximab treatments 
until the threshold of willingness to pay is raised up to $240,000. CONCLUSIONS: 
Our analyses suggest that cetuximab is not cost-effective, either in monotherapy or in 
combination with irinotecan, as the cost-effectiveness ratios are far beyond the 
accepted threshold of $50,000 per QALY gained. Cetuximab treatments need to be 
carefully evaluated before being delivered to metastatic colorectal cancer patients.
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OBJECTIVES: The beneﬁt of screening for and deﬁnitive treatment for prostate cancer 
has been questioned. Results from the Scandinavian study of radical prostatectomy 
compared to watchful waiting for non-screen detected prostate cancer demonstrated 
decrease in prostate cancer speciﬁc mortality, palliative treatment and overall survival. 
We evaluated the cost effectiveness of radical prostatectomy compared to watchful 
waiting using data from the Scandinavian study protocol when extrapolated to the 
US. METHODS: We used the previously reported cost of care data for patients with 
prostate cancer based on the patterns of care observed in the CaPSURE database. The 
data from the Scandinavian trial, in accordance with the study protocol, was used to 
determine the costs and cost-effectiveness of radical prostatectomy for treatment of 
prostate cancer. The cost-effectiveness for radical prostatectomy was determined and 
was adjusted for the costs of androgen deprivation therapy as used in each study arm. 
A model incorporating age at diagnosis, life expectancy and estimate of beneﬁts from 
radical prostatectomy was created that predicts cost effectiveness of surgical interven-
tion for prostate cancer. A sensitivity analysis was performed to test the robustness 
of results. RESULTS: Compared to watchful waiting, radical prostatectomy is associ-
ated with savings of $92,259 per life saved or $4,128 per LYS. When the rate of 
treatment with ADT in each study arm is taken into account, radical prostatectomy 
for treatment of non-screen detected prostate cancer is associated with cost savings of 
$475,297 per life saved or savings of $27,959 per life-year saved compared to the 
costs of watchful waiting. CONCLUSIONS: Radical prostatectomy is a cost effective 
treatment for non-screen detected prostate cancer. Treatment with radical prostatec-
tomy is associated with signiﬁcant cost savings, improved survival, decreased rate of 
metastatic disease and lower rate of palliative care compared to watchful waiting. For 
patients who are surgical candidates watchful waiting is associated with higher mor-
bidity, mortality and costs.
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OBJECTIVES: Compare cost-effectiveness of three non-melanoma skin cancer 
(NMSC) strategies: all Mohs Micrographic Surgery (MMS), all surgical excision and 
mixed MMS and excision. METHODS: A decision-analytic model compared strate-
gies using data from a prospective sample (n = 540) treated with MMS or excision at 
a university-afﬁliated dermatology clinic from 1999–2000. The newest (2007) Medi-
care costing rules with tumor size, location and number of stages for MMS were used. 
Total cost included the procedure, pathology, drugs, 2 month follow-up visits, second-
ary procedures, repairs or grafts and recurrences. Short Form (SF)-12 and Skindex 
scores at baseline and 2 years were mapped to the Health Utility Index (HUI) to adjust 
life expectancy and recurrence, our major outcomes. Cost per quality adjusted life 
year saved (QALYS) was the ﬁnal outcome. Sensitivity analysis tested uncertainty of 
model parameters. RESULTS: The all MMS strategy was most cost-effective when 
compared to mixed (ICER = $30,521/QALYS) and all excision strategies (ICER = 
$6,722/QALYS). The mixed strategy was cost-effective compared to the all excision 
strategy (ICER = $1,924/QALYS). All excision was least costly ($1634.50/patient), 
mixed next ($1681.00/patient) and all MMS was most costly ($1830.10/patient). The 
all MMS strategy (17.2081 QALYS) was most effective compared to mixed (17.2032 
QALYS) and all excision (17.1790 QALYS) strategies. The model is sensitive to the 
proportion of patients who receive MMS versus excision in the mixed strategy. The 
all MMS strategy no longer is cost-effective compared to the mixed strategy when the 
MMS proportion is decreased from 58.8% to 50% (ICER = $2,793,794) and at 45% 
the mixed strategy dominates all other strategies. Not until $900 is added to procedure 
cost for MMS, does the all MMS strategy lose its cost-effectiveness. CONCLUSIONS: 
All MMS for NMSC is the most cost-effective strategy although the mixed strategy is 
preferred in some mixtures of patient populations. This analysis demonstrates that 
MMS is cost-effective if clinically indicated.
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OBJECTIVES: Sorafenib is the only agent that has proven to improve survival in 
AHCC (Llovet, NEJM 2008), and has been considered cost-effective in Canada 
(Muszbek, Curr Med Res Opin 2008), when compared with BSC. In clinical practice 
in Brazil, however, patients with AHCC with no access to sorafenib are often treated 
with other systemic agents, none of which are able to improve the outcome. The objec-
tive of this study was to evaluate the cost-effectiveness of sorafenib+BSC vs BSC alone 
in Brazil, from the perspective of the public health-care system. METHODS: A Markov 
model was developed to project the lifetime survival and costs for both interventions 
using data from the TTP and OS Kaplan-Meier curves from SHARP trial using a log-
normal distribution and an ad hoc panel with Brazilian medical oncologists, hepatolo-
gists, and liver surgeons. Treatment effectiveness was measured in life-years gained 
(LYG). Resource utilization included drug, administration, physician visits, monitor-
ing, and adverse events. Costs (in R$, with R$ 1.00 ∼ US$ 0.58) and survival beneﬁts 
were discounted annually at 5%. Univariate and probabilistic sensitivity analyses were 
conducted. RESULTS: Lifetime per-patient costs in R$ (US$) were 76,032 (43,447) and 
9,776 (5,586) for sorafenib+BSC and BSC alone, respectively. Sorafenib drug cost 
accounted for nearly 79% of treatment costs. The incremental survival beneﬁt with 
sorafenib+BSC was 0.49 life-years. The incremental cost-effectiveness ratio of 
sorafenib+BSC vs BSC alone was R$ 135,262 (US$ 77,293) per LYG. Variations in the 
lognormal parameters for OS of both alternatives demonstrated to be the most inﬂu-
ential variables in the cost-effectiveness result in the deterministic sensitivity analysis. 
CONCLUSIONS: The addition of sorafenib to BSC is the only intervention that has 
been found to improve survival in AHCC and the cost-effectiveness results should be 
interpreted considering the low cost and inefﬁciency of the comparator.
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OBJECTIVES: Multiple myeloma (MM) is a hematologic malignancy mainly affecting 
the elderly population. It is incurable and patients experience a considerable reduction 
of health-related-quality-of-life (HRQoL). Some newer therapies have shown better 
clinical effects but are more costly. Pharmacoeconomic studies on MM have been 
widely conducted overseas but local data was lacking. This study aimed to examine 
the cost-effectiveness of the treatments for MM in Macao, China. METHODS: A 
retrospective cost-effectiveness study with HRQoL assessment was conducted. Forty 
patients from the largest public hospital in Macao from 1997–2007 with conﬁrmed 
MM were studied. Data for costs and treatment effects were extracted from patients’ 
